Xeltis enjoyed its latest success last week when it won gold in medical technology at the Edison Awards Gala in New York. The global awards are now in their 30th edition and recognise persistence and excellence in innovation. Xeltis won for its heart valves and blood vessels that enable cardiovascular restoration using the body’s own tissue.
Xeltis products are made of bioabsorbable polymers structured as a porous matrix designed to work as a valve or other cardiovascular component. Once implanted, the body’s natural healing process pervades it with new functioning tissue. The matrix is then absorbed, leaving the patient with his or her own healthy tissue.
“We are honoured the Edison Award recognised the truly innovative potential of our technology. We are making happen something that sounded impossible: enabling the body to restore its own heart valves and patients to live better lives soon,” Xeltis CEO Laurent Grandidier said in a statement.
Xeltis was founded in 2006 as a spin-off of the University of Zurich. It later merged with the Dutch company Qts/e and has offices in both Eindhoven and Zurich.